Post Radiation Grade 3 neuroendocrine carcinoma (PRNEC): a new entity?
Cancer survivors have a 14% increased risk of developing a malignancy compared with the general population. Second radiation-induced malignancies with different histologies have been described in different organs. Based on individual observations, we hypothesized that Neuroendocrine carcinoma (NEC) could arise in irradiated organs. In a retrospective analysis of Gustave Roussy database of NEC patients (small cell lung cancer excluded) diagnosed as a second cancer, we looked for the frequency of Grade 3 NEC that arose in patients who had received previous radiation therapy for a first cancer. Radiation therapy for the first cancer, dose, location of RT, pathological characteristics, overall survival, response to treatment of secondary neuroendocrine carcinoma were analyzed. From January 1995 to December 2017, 847 cases of NEC were seen at Gustave Roussy. Among them, 95 (11.2%) pts had a history of previous malignancy of which 36 (4%) had been treated with radiation therapy. Out of these 36 patients, 12 (1.4% of all NEC pts) developed a NEC within the previous irradiated organ (median dose of 50 Gy, range 36-67.5)). Most frequent first cancers were breast (n=4) and Hodgkin lymphoma (n=3). NEC arose within a median time from radiation of 21.7 years (range 5.1-36.4) in the thorax (n=5), digestive tract (n=3) and other sites. Five large cell NEC, 3 small Cell NEC, 1 MiNEN and 3 not otherwise specified NEC were diagnosed. Ten patients had stage IV disease at diagnosis; median overall survival was 37.8 months (95% CI [17.6-NA]). Three pts (25%) achieved complete response with multimodal treatment. NEC can arise from previously irradiated organs and may have a better outcome in this setting. Other risk factors should be investigated to explain the high rate of previous cancer in this population of neuroendocrine neoplasm.